Early outcome of machine perfusion vs static cold storage of liver graft: A systemic review and meta-analysis of randomized controlled trials

D Ibrahim Umar Garzali¹, Ali Aloun², Ez el din Abuzeid³, Abdurrahman Abba Sheshe¹

¹Department of Surgery, Aminu Kano Teaching Hospital, Kano, Nigeria; ²Department of Surgery, King Hussein Medical Centre, Amman, Jordan; ³Department of Surgery, Soroka Medical Centre, Be'er Sheva, Israel

Abstract

The use of marginal grafts is very challenging and is associated with post-reperfusion syndrome and early allograft dysfunction. The outcomes of machine perfusion for the preservation of marginal grafts have been compared with that of static cold storage, with studies reporting a reduced risk of ischemic cholangiopathy and graft loss. We performed this systematic review and meta-analysis of randomized controlled trials (RCTs) comparing outcomes of machine perfusion of liver grafts to static cold storage (SCS) of liver grafts during liver transplantation. Two independent researchers thoroughly searched for literature in the following databases: PubMed (Medline), Cochrane Central Register of Controlled Studies (CENTRAL), clinical trial registry, ResearchGate, Google Scholar, and Scopus (ELSEVIER) databases (last search: November 2023). The search terms used were: "dynamic perfusion," "normothermic perfusion," "hypothermic perfusion," "liver transplantation," "static cold storage," "NMP," "HOPE," "extended criteria grafts," "marginal grafts," "RCTs," "randomized controlled trials," "warm ischemia," and "cold ischemia." Eight RCTs published between 2019 and 2023 were included in the data synthesis and meta-analysis. The primary outcome considered was the overall incidence of early allograft dysfunction (EAD) between the two methods of graft perfusion after liver transplantation. The secondary outcome considered was the rate of retransplantation. Our meta-analysis revealed that SCS is associated with more EAD when compared with machine perfusion, with a p-value of <0.00001. We also found that the rate of retransplantation is higher among patients who received a liver preserved by SCS, with a p-value of 0.02. The use of machine perfusion in the preservation of liver grafts showed a significant reduction in early allograft dysfunction and retransplantation.

Keywords: Early allograft dysfunction; liver transplantation; machine perfusion; static cold storage.

How to cite this article: Garzali IU, Aloun A, Abuzeid E, Sheshe AA. Early outcome of machine perfusion vs static cold storage of liver graft: A systemic review and meta-analysis of randomized controlled trials. Hepatology Forum 2024; 5(4):211–216.

Received: December 18, 2023; Revised: February 07, 2024; Accepted: February 20, 2024; Available online: Macrh 22, 2024

Corresponding author: Ibrahim Umar Garzali; Department of Surgery, Aminu Kano Teaching Hospital, Kano, Nigeria

Phone: +2348178940753; e-mail: gazaliumar270@yahoo.co.uk

OPEN ACCESS This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Hepatology Forum - Available online at www.hepatologyforum.org



Introduction

Since liver transplantation became an acceptable therapeutic option for selected liver diseases, there has been a marked increase in the demand for liver grafts, resulting in a lack of adequate ideal grafts for liver transplantation. In an effort to expand the donor pool, transplant surgeons have increasingly used extended criteria grafts, domino liver grafts, and living donor grafts.^[1-3] The use of extended criteria grafts is very challenging and is associated with more complications such as post-reperfusion syndrome, early allograft dysfunction (EAD), primary nonfunction (PNF), and vascular and biliary complications, among others. These complications may be associated with graft loss or even the mortality of patients.^[4-7] One of the risk factors for post-transplant liver dysfunction is ischemic reperfusion injury. Liver transplantation is associated with two forms of liver ischemia, both inducing hepatocellular injury.^[8–10] The first is cold ischemia, which occurs during the retrieval of the graft when the liver is cooled, perfused, and then stored in a cold preservation solution (static cold storage {SCS}). The second form of ischemia is warm ischemia, which is encountered during implantation, from the removal of the organ from ice until reperfusion, or the ischemia encountered during organ retrieval, from the time of cross-clamping (or of asystole in non-heart-beating donors) until cold perfusion is commenced.[11] The graft is metabolically inhibited during warm and cold ischemia and becomes more dysfunctional by reperfusion injury after revascularization and reoxygenation.^[12,13] An ideal graft can tolerate a long period of cold ischemic time with minimal permanent sequelae. However, extended criteria grafts cannot tolerate prolonged periods of ischemia.^[14] To reduce or eliminate these ischemic periods, especially in extended criteria grafts, dynamic preservation techniques using ex situ liver perfusion have been utilized.^[15-17] There are two main types of ex situ liver perfusion that are clinically available. The first method is hypothermic oxygenated perfusion (HOPE), which utilizes a highly oxygenated (pO2:>60 kPa) artificial solution at hypothermic temperatures $(8-12^{\circ}C)$. This method is routinely performed after the transport of the graft to the recipient center, so it is considered end-ischemic. The second method of ex situ perfusion is normothermic machine perfusion (NMP), which aims for a "near-physiological" environment. It utilizes a blood-based perfusate to perfuse the graft at 37 °C.^[15–17] The outcomes of dynamic perfusion have been compared with that of static cold storage, with initial studies reporting a reduced risk of ischemic cholangiopathy and graft loss in patients who received machine perfusion when compared to static cold storage.^[18] We perform this systematic review and meta-analysis of randomized controlled trials comparing the outcome of machine perfusion of liver grafts compared to SCS of liver grafts during liver transplantation.

Methods

This systematic review was performed in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We prospectively registered the protocol for this systematic review in the International Prospective Register of Systematic Reviews, PROSPERO (CRD42023481913). Search strategy Two independent researchers thoroughly searched for literature in the following databases: PubMed (Medline), Cochrane Central Register of Controlled Trials (CENTRAL), clinical trial registry, ResearchGate, Google Scholar, and Scopus (ELSEVIER) databases (last search: November 2023). The search terms used were: "dynamic perfusion," "normothermic perfusion," "hypothermic perfusion," "liver transplantation," "static cold storage," "NMP," "HOPE," "extended criteria grafts," "marginal grafts," "RCTs," "randomized controlled trials," "warm ischemia," and "cold ischemia." The terms were combined using Boolean logic. Related articles and reference lists were searched to ensure the completeness of the search. Conflict was resolved by involving a third researcher. Eligibility criteria The inclusion criteria for a study to be included in the review are as follows: 1. Studies published from 1990 to date. 2. Randomized controlled trials that compared outcomes of liver transplantation in patients whose graft was preserved using SCS and those whose grafts were preserved using machine perfusion. 3. Studies with full texts. Exclusion criteria are as follows: 1. Conference presentations, editorials, and commentaries. 2. Studies in which the relevant data are absent. 3. Studies with a total sample size of fewer than 10. Quality assessment and risk of bias assessment The Jadad score, which was developed by Jadad et al.,^[19] was used to assess the quality and bias of the included RCTs. The score ranges from 0-5. A score of 3 and above was considered a good quality study. Publication bias If 10 or more studies were included in the meta-analysis of a particular outcome, then publication bias was evaluated using a funnel plot. Data extraction Data extraction was performed by 2 independent researchers. The following information was extracted from each study: first author, year of manuscript publication, study design, number of patients in each group, gender of patients per group, mean age of patients in each group, type of organ preservation technique, and outcome data. In case of conflicts between the two researchers, a third researcher was involved to resolve the conflict. Outcome The primary outcome of interest is the incidence of PNF per group. The secondary outcome of interest includes the incidence of EAD per group. Other outcomes of interest include post-reperfusion syndrome, incidence of retransplantation, vascular complication, biliary complication, ICU stay, mortality, and graft survival at 1 year. Statistical



Figure 1. Study selection process.

analysis Statistical analyses were done using RevMan software (version 5.4.1). If the variable is dichotomous, the pooled risk ratio (RR) was calculated with a 95 percent confidence interval. However, if the variable is continuous, the weighted mean difference or standardized mean difference with a 95 percent CI was calculated from the mean and standard deviation reported from individual studies. If a study did not report the mean and standard deviation, the Wan et al.^[20] method of extracting mean and standard deviation from the median and interquartile range was utilized. A fixed-effects model was used to calculate the pooled effect sizes if the data were not significantly heterogeneous. Otherwise, a random-effects model was used. Heterogeneity was assessed using the I² statistics. I²>50% was considered as statistically significant heterogeneity. Sensitivity analysis was done by sequential elimination of each of the included studies in the meta-analysis to identify the main source of heterogeneity. Publication bias was evaluated using the funnel plot and Egger's test if 10 or more studies were included in the meta-analysis of a particular outcome, as recommended by the Cochrane handbook.

S/N	Author	Year of publication	Sample size	e per group	Jadad score	Quality of the study		
			SCS MP					
1	Schlegel et al.	2023	85	85	4	Good quality		
2	Van Rijn et al.	2021	78	78	4	Good quality		
3	Ravaioli et al.	2022	55	55	4	Good quality		
4	Ghinolfi et al.	2019	10	10	4	Good quality		
5	Markman et al .	2022	142	151	3	Good quality		
6	Czigany et al.	2021	23	23	4	Good quality		
7	Grat et al.	2023	78	26	3	Good quality		
8	Nasralla et al.	2019	101	121	3	Good quality		

	SCS		MP		Risk Ratio			Risk Ratio				а
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	{ 	M	I-H, Fixed, 95% CI		
Nasralla 2018	29	101	12	121	12.8%	2.90 [1.56, 5.38]	2018					
Ghinolfi 2019	1	10	2	10	2.3%	0.50 [0.05, 4.67]	2019		<u> </u>	<u> </u>		
Van Rijn 2021	31	78	20	78	23.4%	1.55 [0.97, 2.47]	2021					
Czigany 2021	8	23	4	23	4.7%	2.00 [0.70, 5.73]	2021			+		
Markmann 2022	44	142	27	151	30.6%	1.73 [1.14, 2.64]	2022					
Ravaioli 2022	19	55	7	55	8.2%	2.71 [1.24, 5.93]	2022					
Schlegel 2023	39	85	14	85	16.4%	2.79 [1.64, 4.74]	2023					
Grat 2023	12	78	1	26	1.8%	4.00 [0.55, 29.30]	2023					-
Total (95% CI)		572		549	100.0%	2.11 [1.69, 2.65]				•		
Total events	183		87							1.1.0		
Heterogeneity: Chi ² =	6.98, df=	7 (P=	0.43); I ² =	= 0%				0.01	01		10	100
Test for overall effect:	Z=6.48 ((P < 0.0	00001)					0.01	0.1	SCS MP	10	100
	SCS		HMF	b		Odds Ratio				Odds Ratio		b
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Fixed, 95% Cl	Year		M	H. Fixed, 95% CI		
Van Riin 2021	31	78	20	78	42.9%	1 91 [0 97 3 78]	2021					
Crigony 2021		22	20	22	0.2%	2 52 10 64 10 05	2021				_	
Devoiali 2021	10	23	4 7	25	16.00	2.03 [0.04, 10.00]	2021					
Ravaluli 2022	19	55		55	10.3%	3.02 [1.37, 9.53]	2022				_	
Schlegel 2023	39	85	14	85	27.0%	4.30 [2.10, 8.78]	2023				100	
Grat 2023	12	78	1	26	4.5%	4.55 [0.56, 36.80]	2023					
Total (95% CI)		319		267	100.0%	3.01 [2.01, 4.52]				•		
Total events	109		46									
Heterogeneity: Chi ² =	3.01. df =	4 (P =	0.56); 17:	= 0%				<u> </u>			+	
Test for overall effect:	Z = 5.31 (19420192				0.01	0.1	1	10	100		
			,							SCS HMP		
	SCS	;	NMF)		Risk Ratio				Risk Ratio		С
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	-	M	I-H, Fixed, 95% CI		
Nasralla 2018	29	101	12	121	27.9%	2.90 [1.56, 5.38]	2018					
Ghinolfi 2019	1	10	2	10	5.1%	0.50 [0.05, 4.67]	2019		2	-		
Markmann 2022	44	142	27	151	67.0%	1 73 [1 14 2 64]	2022					
					01.070		LOLL			Sec. Sec.		
Total (95% CI)		253		282	100.0%	1.99 [1.42, 2.80]				•		
Total events	74		41									
Heterogeneity: Chi ² =	0.19) 17:					+						
Tact for overall effect	7-2004	0,00	0001					0.01	0.1	1	10	100
restion overall effect.	2 - 3.30 (, - 0.0	,001)							SCS NMP		

Figure 2. (a) Meta-analysis comparing early allograft dysfunction between MP and SCS. (b) Meta-analysis comparing early allograft dysfunction between HMP and SCS. (c) Meta-analysis comparing early allograft dysfunction between NMP and SCS.

Results

Results were reported in accordance with the PRISMA checklist.

Study Selection Process and Description of Selected Studies

We identified 5,473 references during the initial search. Out of these, 5,321 articles were excluded because of duplicate publications (Fig. 1). The 152 remaining references were further assessed in terms of titles and abstracts. One hundred and thirty-two references were excluded for lack of relevant data. Twenty full-text articles were retrieved, but 12 articles were excluded for lack of a control arm. Eight were included for data synthesis and meta-analysis.^[21–28] The studies included were all randomized controlled trials (RCTs) published from 2019 to 2023. Five of the studies^[21–23,27,28] compared SCS to HOPE, while three of the studies^[24–26] compared SCS to NMP. Details of selected studies are displayed in Table 1.

Primary Outcome

Early Allograft Dysfunction

The primary outcome compared was the overall incidence of EAD be-

tween the two methods of graft perfusion after liver transplantation. All eight included studies^[21–28] compared the incidence of EAD. In our metaanalysis, we found that patients who received a liver graft preserved with machine perfusion tend to have a lower incidence of EAD. The difference between the two groups was statistically significant with a RR of 6.48 and a p<0.00001. There was no significant heterogeneity between the studies with I²=0% (Fig. 2a). Publication bias was assessed by visual inspection of the funnel plot and was found to be symmetrical, revealing no bias.

We also performed a subgroup analysis comparing the various methods of machine perfusion to SCS. We found that hypothermic machine perfusion is associated with less EAD when compared to SCS (Fig. 2b, RR=5.31, p<0.0001). A similar finding was also observed when NMP was compared to SCS (Fig. 2c, RR=3.98, p<0.00001).

Secondary Outcomes

Post Reperfusion Syndrome

Four studies^[22–25] comprising 496 patients compared post-reperfusion syndrome between the two groups of patients. Our pooled meta-analysis revealed that PRS occurred in 92 patients who received a



SCS				MP			Risk Ratio					Risk Ratio			
Study or Subgroup	Events	s Tota	I Even	ts T	otal	Weight	M-H, I	Random, 95% Cl	Year		N	I-H, Random,	95% CI		
Nasralla 2018	3:	2 101	1 1	15	121	28.7%		2.56 [1.47, 4.45]	2018						
Ghinolfi 2019		1 10)	3	10	7.2%		0.33 [0.04, 2.69]	2019				-		
Van Rijn 2021	33	3 72	2 2	20	72	31.2%		1.65 [1.05, 2.59]	2021			-	 .		
Ravaioli 2022	20	6 55	5 3	30	55	32.9%		0.87 [0.60, 1.25]	2022						
Total (95% CI)		238	3		258	100.0%	e e	1.35 [0.73, 2.51]				-			
Total events	93	2	6	68						101	0.650		01	0.0	
Heterogeneity: Tau ² =	= 0.27; C	hi² = 13	1.52, df=	= 3 (F	P = 0.0)04); I ² =	= 78%			0.01	01		10	100	
Test for overall effect	: Z = 0.95	5 (P = 0	.34)							0.01	0.1	SCS MP	10	100	
	S	CS		MP			F	tisk Ratio				Risk Rati	D	b	
Study or Subgroup	Event	s Tota	al Ever	nts	Total	Weigl	nt M-H	, Fixed, 95% Cl	Year		1	M-H, Fixed, 95	5% CI		
Nasralla 2018		0 10	1	1	121	35.3	% 0	.40 [0.02, 9.68]	2018			-			
Ghinolfi 2019		0 1	0	0	10			Not estimable	2019			<.<			
Van Rijn 2021		1 7	8	0	78	12.9	% 3.0	00 [0.12, 72.53]	2021			100	-		
Czigany 2021		1 2	3	1	23	25.9	% 1.0	00 [0.07, 15.04]	2021						
Markmann 2022		0 14	2	0	151	12.0	× 5.00	Not estimable	2022						
Schlegel 2022		2 3	5	0	95	12.9	% 5.00 % 7.00	0 [0.25, 101.81]	2022						
ochieger 2025		5 0	×	0	00	12.0	<i>x</i> ,	[0.07, 100.40]	2025						
Total (95% CI)		49	4		523	100.0	% 2.	34 [0.72, 7.65]							
Total events		7		2											
Heterogeneity: Chi ² :	= 2.36, d	f=4 (P	= 0.67)); l ² =	0%					0.01	01		10	100	
Test for overall effect	t: Z = 1.4	1 (P = ().16)							0.01	0.1	SCS MP	10	100	
	S	CS			MP			Mean Differenc	е			Mean Diffe	rence	с	
Study or Subgroup	Mean	SD 1	otal M	lean	SD	Total	Weight	IV, Random, 95%	CI Y	ear		IV, Random,	95% CI		
Nasralla 2018	4.67	3.44	101	4.33	4.3	121	22.7%	0.34 [-0.68, 1	.36] 21	018					
Czigany 2021	10.33	0.27	23	5.67	316	23	2.8%	4 66 10 27 9	051 21	021		-			
Van Riin 2021	2 22	2.67	78	2	2 27	79	27 5%	-0.67 [1.45 0	111 2	121					
Devoiali 2021	4.00	2.07	55	5	2.21	55	20.00	0.07 [-1.43, 0	501 20	221					
Ravaloli 2022	4.33	2.28	55	5	3.81	55	20.0%	-0.67 [-1.84, 0	.5UJ 21	322					
Schlegel 2023	3.67	3.01	85	3.33	2.26	85	27.0%	0.34 (-0.46, 1	.14] 21	023					
Total (95% CI)			342			362	100.0%	-0.02 [-0.78, 0.	.74]			-	•		
Heterogeneity: Tau ² =	0.39: Chi	² = 9.36	df = 4 ((P = 0)	.05); P	= 57%				5 <u> </u>				Y	
Test for overall effect	7 - 0.05 /	P - 0.00	3								-2	-1 0	1 2	2	
restion overall effect.	L = 0.03 (- 0.90	"									SCS M	P		

Figure 3. (a) Meta-analysis comparing post reperfusion syndrome between MP and SCS. (b) Meta-analysis comparing primary non-function between HMP and SCS. (c) Meta-analysis comparing ICU stay between NMP and SCS.

liver graft preserved with SCS as opposed to 68 patients whose liver grafts were preserved using machine perfusion. This difference was not statistically significant with an RR of 0.95 and a p-value of 0.34. There was significant heterogeneity among studies included in the meta-analysis with $I^2=78\%$, so the random effect model was used to estimate the pooled effect size. The detailed meta-analysis of post-reperfusion syndrome is displayed in Figure 3a.

Primary Non-Function and Ischemic Cholangiopathy

Seven of the studies^[21–27] included compared primary non-function (PNF) between the two methods of liver graft preservation. The pooled sample size of the studies is 523 patients in the machine perfusion group and 494 patients in the SCS group. Pooled analysis revealed that 7 patients had PNF in the SCS group while only 2 patients had PNF in the machine perfusion group. However, this difference was not statistically significant with an RR of 1.41 and a p-value of 0.16. There was no significant heterogeneity between the included studies with an I²=0%. The detailed meta-analysis of PNF is displayed in Figure 3b.

Ischemic cholangiopathy was compared in only two studies^[24,25] among included randomized controlled trials. Our pooled analysis showed that 3 out of 111 grafts preserved by SCS developed ischemic cholangiopathy as opposed to 2 out of 121 grafts preserved

with machine perfusion. The difference is not statistically significant with a RR of 0.56 and a p-value of 0.57.

Duration of Stay in Intensive Care Unit

Five studies^[21–23,25,27] consisting of 702 patients compared the duration of stay in the intensive care unit (ICU) between machine perfusion and SCS of liver graft. Pooled analysis of these studies revealed that the duration of stay in the ICU is similar among the two groups of patients with a mean difference of 0.05 and a p-value of 0.96. There was significant heterogeneity among the studies included in the analysis with an I²=57%, so the random effect model was used in estimating the pooled effect size. The detailed meta-analysis of ICU stay is displayed in Figure 3c.

Retransplantation

Five studies^[21–23,25,27] consisting of 702 patients compared the rate of retransplantation between machine perfusion and SCS of liver graft. Pooled analysis of these studies revealed that the rate of retransplantation is higher among patients who received a liver that was preserved by SCS. The difference was found to be statistically significant with an RR of 2.30 and a p-value of 0.02. There was no heterogeneity between the studies included in the analysis with an I²=0%. The detailed and graphical representation of this meta-analysis is displayed in Figure 4.

	SCS	;	MP		Risk Ratio			Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fixed, 95% Cl				
Nasralla 2018	2	101	3	121	35.3%	0.80 [0.14, 4.69]	2018					
Czigany 2021	2	23	1	23	12.9%	2.00 [0.19, 20.55]	2021					
Van Rijn 2021	6	78	3	78	38.8%	2.00 [0.52, 7.71]	2021					
Ravaioli 2022	6	55	0	55	6.5%	13.00 [0.75, 225.30]	2022					
Schlegel 2023	3	85	0	85	6.5%	7.00 [0.37, 133.48]	2023					
Total (95% CI)		342		362	100.0%	2.61 [1.15, 5.91]		◆				
Total events	19		7									
Heterogeneity: Chi² = 3.57, df = 4 (P = 0.47); l² = 0%												
Test for overall effect:	Z = 2.30 ((P = 0.0)2)					SCS MP				

Figure 4. Meta-analysis comparing retransplantation between MP and SCS.

Discussion

The increased demand for liver grafts has led to a scarcity of donors, resulting in the heightened use of extended criteria donors or marginal donors. The definition of a marginal or extended criteria donor varies, but the term is commonly used to describe grafts obtained from donors aged above 65 years, donors who have spent at least 7 days in the ICU, obese donors, donors with fatty livers, prolonged cold ischemia time of over 12 hours, and donors with elevated liver enzymes or hypernatremia at any time.^[29,30] Reports suggest that extended criteria donors may constitute up to 50% of total liver donors in some European countries.^[4,31,32] A persistent problem associated with the use of extended criteria donation is that the grafts are susceptible to ischemic reperfusion injury, resulting in an increased risk of EAD and primary non-function. ^[33–35] These complications predispose recipients to an increased risk of sepsis, graft loss, longer stays in the ICU, and longer hospital stays.^[18]

One of the main aims of machine perfusion is to reduce ischemic reperfusion injury and, by extension, reduce the risk of EAD and its complications.^[18,36] Excellent results have been reported with the use of machine perfusion in the preservation of marginal kidney grafts. Initial reports on the use of machine perfusion for graft preservation have also been encouraging, with reports of reduced risk of ischemic cholangiopathy and graft loss in patients who received machine perfusion compared to static cold storage.^[18,36] In this meta-analysis, we compared early outcomes among patients whose grafts were preserved by SCS and machine perfusion.

Our meta-analysis revealed that machine preservation of liver grafts is associated with a reduced risk of EAD compared to SCS. We also performed a subgroup analysis and found that both hypothermic machine perfusion and NMP are associated with a reduced risk of EAD, similar to previous meta-analyses by Jia et al.,^[18] Yang et al.,^[36] and Parente et al.^[37] The reduction in EAD among grafts preserved by machine perfusion may be a result of the reduction in ischemic reperfusion injury after machine preservation. In our meta-analysis, patients whose grafts were preserved with machine perfusion tended to have less post-reperfusion syndrome compared to SCS, but the difference was not significant. However, there was marked heterogeneity among the included studies. We also found a reduction in primary non-function among grafts preserved with machine perfusion, but the difference was not statistically significant compared to SCS, similar to the findings of Jia et al.^[18] and Parente et al.^[37]

Retransplantation after liver transplantation is a dreaded complication and can be due to a multitude of factors, including vascular complications, technical issues, immunological tissue rejection, allograft dysfunction, or non-function.^[38,39] In this meta-analysis, we found that the rate of retransplantation is higher among patients who had SCS preservation of their liver graft. This may be related to the increased risk of EAD and the tendency for primary non-function to occur in this group of patients, as reported by Yang et al.^[36] and Parente et al.^[37]

Some limitations of this meta-analysis include the fact that some studies have small sample sizes, making them susceptible to higher risks of bias. Additionally, the fact that only studies published in English were included poses a potential for overlooking studies not published in English.

Conclusion

The use of machine perfusion in the preservation of liver grafts showed a significant reduction in EAD and retransplantation compared to static cold storage.

Acknowledgements: The authors want to acknowledge the management and staff of Aminu Kano Teaching Hospital for their contribution during literature search and analysis.

Author Contributions: Concept – IUG, AA, EEDA, AAS; Design – IUG, AA, EEDA, AAS; Supervision – IUG, AA, EEDA, AAS; Fundings – IUG, AA, EEDA, AAS; Materials – IUG, AA, EEDA, AAS; Data Collection and/or Processing – IUG, AA, EEDA, AAS; Analysis and/or Interpretation – IUG, AA, EEDA, AAS; Literature Search – IUG, AA, EEDA, AAS; Writing – IUG, AA, EEDA, AAS; Critical Reviews – IUG, AA, EEDA, AAS.

Conflict of Interest: The authors have no conflict of interest to declare.

Use of AI for Writing Assistance: Not declared.

Financial Disclosure: The authors declared that this study has received no financial support.

Peer-review: Externally peer-reviewed.

References

- 1. Jiménez-Romero C. Using old liver grafts for liver transplantation: Where are the limits? World J Gastroenterol 2014;20(31):10691. [CrossRef]
- Patrono D, De Stefano N, Vissio E, Apostu AL, Petronio N, Vitelli G, et al. How to preserve steatotic liver grafts for transplantation. J Clin Med 2023;12(12):3982. [CrossRef]
- Goldaracena N, Cullen JM, Kim D-S, Ekser B, Halazun KJ. Expanding the donor pool for liver transplantation with marginal donors. Int J Surg 2020;82:30-35. [CrossRef]
- Widmer J, Eden J, Carvalho MF, Dutkowski P, Schlegel A. Machine perfusion for extended criteria donor livers: what challenges remain? J Clin Med 2022;11(17):5218. [CrossRef]

- Neves DB, Rusi MB, Diaz LGG, Salvalaggio P. Primary graft dysfunction of the liver: definitions, diagnostic criteria and risk factors. Einstein (São Paulo) 2016;14(4):567-572. [CrossRef]
- Malkawi D, Savsani K, Alfonso A, Lee SD, James N, Sarkar D, et al. The Role of normothermic machine perfusion in extended criteria donor grafts: a new direction in liver graft assessment and preservation. Livers 2023;3(4):709-726. [CrossRef]
- Ahmed E, El-Badry A, Mocchegiani F, Montalti R, Hassan A, Redwan A, et al. Impact of graft steatosis on postoperative complications after liver transplantation. Surg J 2018;04(04):e188-e196. [CrossRef]
- Liu J, Man K. Mechanistic insight and clinical implications of ischemia/ reperfusion injury post liver transplantation. Cell Mol Gastroenterol Hepatol 2023;15(6):1463-1474. [CrossRef]
- Obed A, Alsakarneh S, Abuassi M, Bashir A, Ahmad BA, Jarrad A, et al. Ischemic reperfusion injury after liver transplantation: Is there a place for conservative Management? Gastroenterol Res 2023;16(1):50-55. [CrossRef]
- Rampes S, Ma D. Hepatic ischemia-reperfusion injury in liver transplant setting: mechanisms and protective strategies. J Biomed Res 2019;33(4):221.
- Halazun KJ, Al-Mukhtar A, Aldouri A, Willis S, Ahmad N. Warm ischemia in transplantation: Search for a consensus definition. Transplant Proc 2007;39(5):1329–1331. [CrossRef]
- Soares ROS, Losada DM, Jordani MC, Évora P, Castro-e-Silva O. Ischemia/reperfusion injury revisited: An overview of the latest pharmacological strategies. Int J Mol Sci 2019;20(20):5034. [CrossRef]
- Czigany Z, Lurje I, Schmelzle M, Schöning Wöllinger R, Raschzok Net al. Ischemia-reperfusion injury in marginal liver grafts and the role of hypothermic machine perfusion: molecular mechanisms and clinical implications. J Clin Med 2020;9(3):846. [CrossRef]
- Pradat P, Pantel S, Maynard M, Lalande L, Thevenon S, Adam R, et al. Endischemic hypothermic oxygenated perfusion for extended criteria donors in liver transplantation: a multicenter, randomized controlled trial—HOPExt. Trials 2023;24(1):379. [CrossRef]
- Tchilikidi KY. Liver graft preservation methods during cold ischemia phase and normothermic machine perfusion. World J Gastrointest Surg 2019;11(3):126-142. [CrossRef]
- Schlegel A, Mergental H, Fondevila C, Porte RJ, Friend PJ, Dutkowski P. Machine perfusion of the liver and bioengineering. J Hepatol 2023;78(6):1181-1198. [CrossRef]
- Brüggenwirth IMA, van Leeuwen OB, de Vries Y, Bodewes SB, Adelmeijer J, Wiersema-Buist J, et al. Extended hypothermic oxygenated machine perfusion enables ex situ preservation of porcine livers for up to 24 hours. JHEP Rep 2020;2(2):100092.[CrossRef]
- Jia J, Nie Y, Li J, Xie H, Zhou L, Yu J, et al. A systematic review and metaanalysis of machine perfusion vs. static cold storage of liver allografts on liver transplantation outcomes: The future direction of graft preservation. Front Med (Lausanne) 2020;7:135. [CrossRef]
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17(1):1-12. [CrossRef]
- Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14(1):135. [CrossRef]
- Schlegel A, Mueller M, Muller X, Eden J, Panconesi R, von Felten S, et al. A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation. J Hepatol 2023;78(4):783-793. [CrossRef]

- van Rijn R, Schurink IJ, de Vries Y, van den Berg AP, Cortes Cerisuelo M, Darwish Murad S, et al. Hypothermic machine perfusion in liver transplantation — A randomized trial. N Engl J Med 2021;384(15):1391-1401. [CrossRef]
- Ravaioli M, Germinario G, Dajti G, Sessa M, Vasuri F, Siniscalchi A, et al. Hypothermic oxygenated perfusion in extended criteria donor liver transplantation—A randomized clinical trial. Am J Transplant 2022;22(10):2401-2408. [CrossRef]
- Ghinolfi D, Rreka E, De Tata V, Franzini M, Pezzati D, Fierabracci V, et al. Pilot, open, randomized, prospective trial for normothermic machine perfusion evaluation in liver transplantation from older donors. Liver Transpl 2019;25(3):436-449. [CrossRef]
- Nasralla D, Coussios CC, Mergental H, Akhtar MZ, Butler AJ, Ceresa CDL, et al. A randomized trial of normothermic preservation in liver transplantation. Nature 2018;557(7703):50-56. [CrossRef]
- Markmann JF, Abouljoud MS, Ghobrial RM, Bhati CS, Pelletier SJ, Lu AD, et al. Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant. JAMA Surg 2022;157(3):189. [CrossRef]
- 27. Czigany Z, Pratschke J, Froněk J, Guba M, Schöning W, Raptis DA, et al. Hypothermic oxygenated machine perfusion reduces early allograft injury and improves post-transplant outcomes in extended criteria donation liver transplantation from donation after brain death. Ann Surg 2021;274(5):705-712. [CrossRef]
- Grat M, Morawski M, Zhylko A, Rykowski P, Krasnodębski M, Wy-porski A, et al. Routine end-ischemic hypothermic oxygenated machi**pe**rfusion in liver transplantation from donors after brain death. Ann Surg 2023;278(5):662-668. [CrossRef]
- Nair A, Hashimoto K. Extended criteria donors in liver transplantation from marginality to mainstream. HepatoBiliary Surg Nutr 2018;7(5):386-388. [CrossRef]
- Lozanovski V, Kerr L, Khajeh E, Ghamarnejad O, Pfeiffenberger J, Hoffmann K, et al. Liver grafts with major extended donor criteria may expand the organ pool for patients with hepatocellular carcinoma. J Clin Med 2019;8(10):1692. [CrossRef]
- Durand F, Renz JF, Alkofer B, Burra P, Clavien P-A, Porte RJ, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transplant 2008;14(12):1694-1707. [CrossRef]
- Metin O, Şimşek C, Gürakar A. Update on liver transplantation-newer aspects. Turk J Med Sci 2020;50(SI-2):1642-1650. [CrossRef]
- Agostini C, Buccianti S, Risaliti M, Fortuna L, Tirloni L, Tucci R, et al. Complications in post-liver transplant patients. J Clin Med 2023;12(19):6173.
- Dery KJ, Yao S, Cheng B, Kupiec-Weglinski JW. New therapeutic concepts against ischemia-reperfusion injury in organ transplantation. Expert Rev Clin Immunol 2023;19(10):1205-1224. [CrossRef]
- 35. Cursio R, Gugenheim J. Ischemia-reperfusion injury and ischemic-type biliary lesions following liver transplantation. J Transplant 2012;2012:1-17.
- Yang X, Li Y, Guo Q, Li Y, Zhong X. Effectiveness of machine perfusion in liver transplantation: A meta-analysis of randomized controlled trials. J Liver Transplant 2023;12:100176. [CrossRef]
- Parente A, Tirotta F, Pini A, Eden J, Dondossola D, Manzia TM, et al. Machine perfusion techniques for liver transplantation - A meta-analysis of the first seven randomized-controlled trials. J Hepatol 2023;79(5):1201-1213.
- Bekker J, Ploem S, De Jong KP. Early hepatic artery thrombosis after liver transplantation: A systematic review of the incidence, outcome and risk factors. Am J Transplant 2009;9(4):746-757. [CrossRef]
- Piardi T. Vascular complications following liver transplantation: A literature review of advances in 2015. World J Hepatol 2016;8(1):36. [CrossRef]